NEW YORK, Feb. 22, 2015 /PRNewswire/ -- Novogen Ltd (ASX:
'NRT'; Nasdaq: 'NVGN'), an Australian-US drug discovery company
focused on the clinical development of drugs targeting two novel
drug targets pertinent to a range of therapeutic indications,
announced today that Graham Kelly,
PhD, CEO and Executive Chairman, will present at the
3rd Annual SACHS Cancer Bio Partnering and Investment
Forum on Monday 23rd February
2015 at 2.30 pm EST at the New York Academy of
Sciences.
A copy of the presentation with audio will be available on the
Company's website www.novogen.com at 2.30 pm
EST.
About Novogen Limited
Novogen is a public, drug-development company whose shares trade
on both the Australian Securities Exchange ('NRT') and NASDAQ
('NVGN'). The Novogen Group includes a New Haven CT -- based joint venture company,
CanTx Inc., with Yale University.
Novogen has two Novogen has two main drug technology platforms:
super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP
compounds have been created to kill the full range of cells within
a tumor, but particularly the cancer stem cells. The ATM
compounds target the microfilament component of the cancer cell and
when used in conjunction with standard anti-microtubular drugs,
result in comprehensive and fatal destruction of the cancer cell's
cytoskeleton. Ovarian cancer, colorectal cancer, malignant
ascites, prostate cancer, neural cancers (glioblastoma,
neuroblastoma in children) and melanoma are the key clinical
indications being pursued, with the ultimate objective of employing
both technologies as a unified approach to first-line therapy.
Further information is available on our websites
www.novogen.com
For more information please contact:
Corporate
Contact
Dr. Graham
Kelly
Executive Chairman
& CEO
Novogen
Group
Graham.Kelly@novogen.com
+61 (0) 2 9472
4100
|
Media
Enquiries
Cristyn
Humphreys
Chief Operating
Officer
Novogen
Group
Cristyn.Humphreys@novogen.com
+61 (0) 2 9472
4111
|
Forward Looking Statement
This press release contains "forward-looking statements"
within the meaning of section 27A of the Securities Act of 1933 and
section 21E of the Securities Exchange Act of 1934. The
Company has tried to identify such forward-looking statements by
use of such words as "expects," "appear," "intends," "hopes,"
"anticipates," "believes," "could," "should," "would," "may,"
"target," "evidences" and "estimates," and other similar
expressions, but these words are not the exclusive means of
identifying such statements. Such statements include, but are
not limited to any statements relating to the Company's drug
development program, including, but not limited to the initiation,
progress and outcomes of clinical trials of the Company's drug
development program, including, and any other statements that are
not historical facts. Such statements involve risks and
uncertainties, including, but not limited to, those risks and
uncertainties relating to the difficulties or delays in financing,
development, testing, regulatory approval, production and marketing
of the Company's drug components, including, but not limited to the
ability of the Company to procure additional future sources of
financing, unexpected adverse side effects or inadequate
therapeutic efficacy of the Company's drug compounds, including,
but not limited to events that could slow or prevent products
coming to market, the uncertainty of patent protection for the
Company's intellectual property or trade secrets, including, but
not limited to, the intellectual property relating to the Company's
two proprietary technology platforms, and other risks detailed
from time to time in the filings the Company makes with Securities
and Exchange Commission including its annual reports on Form 20-F
and its reports on Form 6-K. Such statements are based on
management's current expectations, but actual results may differ
materially due to various factions including those risks and
uncertainties mentioned or referred to in this press release.
Accordingly, you should not rely on those forward-looking
statements as a prediction of actual future results.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/novogen-to-present-at-sachs-cancer-bio-partnering--investment-forum-300039474.html
SOURCE Novogen Limited